1Q-24 Quarterly Results Cautionary Note • This presentation contains, and the officers of Teladoc Health, Inc. (the “Company” or “Teladoc Health”) may make, “forward-looking” statements that are based on management’s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of the Company’s business plan and strategies. These statem ...

公司业绩展望 - 公司预计2024年3月31日季度和2024年12月31日年度的业绩展望与2024年2月20日的财报中披露的展望范围一致[4] 高管任命及薪酬调整 - 公司任命Mala Murthy为代理首席执行官，取代Jason Gorevic，同时继续担任首席财务官[5] - Mala Murthy的基本工资将从53万美元增加至约75万美元，目标奖金机会将从基本工资的75%增加至120%[5]

Teladoc Health, Inc. (TDOC) is set to report its first-quarter 2024 results on Apr 25, after the closing bell. Analysts anticipate a robust performance in the Integrated Care segment, although rising costs may partially offset its results. Let’s delve deeper. Factors Impacting TDOC Teladoc’s top line has been benefiting on the back of higher Access Fees, visits and segmental growth in Integrated Care. Growth in U.S. Integrated Care members is likely to have fueled growth in its first-quarter results. Our es ...

Has the telehealth provider entered value territory? Investor sentiment surrounding Teladoc (TDOC -1.20%) has been bad for a while now. The telemedicine specialist's stock is down 95% from its all-time high in 2021. Teladoc's business boomed during the early days of the COVID-19 pandemic, benefiting enormously by providing at-home virtual care to patients. But like so many of the other "stay-at-home" stocks, Teladoc has struggled mightily since life returned to normal. The company is not currently profitabl ...

PURCHASE, NY, April 12, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, announced that it will release first quarter 2024 results on Thursday, April 25, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 901506. For internationa ...

公司现状 - Teladoc Health的股价自COVID-19大流行期间创下的最高点以来已经暴跌，跌幅约为95%[1] - 公司CEO Jason Gorevic自2009年以来已经离职，董事会尚未选定永久接任者[2] - Teladoc Health是全美最具可及性的远程医疗服务提供商，截至2023年底，约有9000万美国人可以使用其产品和服务[4] 财务状况 - Teladoc Health的底线正在增长，去年调整后的息税折旧摊销前利润（EBITDA）增长了33%，达到3.28亿美元[7] - 公司去年亏损2.2亿美元，预计今年也将出现重大的GAAP亏损[9] - Teladoc的营收主要来自访问费，但提高这些费用以实现稳定增长的利润可能比投资者意识到的更具挑战性[12] 业务表现 - 公司在2023年完成的远程医疗就诊次数仅为1840万次，尽管有8000万美国人可以使用其产品和服务[13] - Teladoc Health股票目前不宜买入，但已持有的投资者可能希望继续持有，以查看朝着可持续盈利的趋势是否持续[17]

CEO离职 - Teladoc Health的CEO Jason Gorevic突然离职，由现任CFO Mala Murthy代理接任[1] - 公司未明确解释Gorevic离职的原因，董事会正在寻找继任者[2] - 董事会对Gorevic的离职表示感谢，对代理CEO Murthy给予赞扬，但尚未明确表示她是否合格长期担任CEO[3] 股价波动 - 公司股价在CEO离职消息发布后出现波动，但最终回升[1] 公司财务状况 - Teladoc虽然从未盈利，但去年产生了3.39亿美元的正向自由现金流，债务水平适中，公司的股价对自由现金流的比率看起来很合理[5]

Teladoc Health股票动态 - Teladoc Health (NYSE:TDOC)股票因CEO Jason Gorevic辞职的消息而备受关注[1] - CFO Mala Murthy将暂时接任Gorevice的职务，公司将寻找永久接替者[2] - Gorevice自2019年以来一直领导Teladoc，掌控了公司在Covid-19大流行期间的局势[3] - Covid-19期间对虚拟医生就诊的需求激增，导致TDOC股票出现强劲增长，但自2021年以来股价下跌了95%[4] Teladoc Health未来展望 - Teladoc的未来目前尚不明朗，产品需求在Covid-19大流行结束后有所下降，同时面临来自其他在大流行期间涌现的虚拟医疗公司的竞争[5] - 所有这些因素给TDOC股票带来了额外的压力，Teladoc董事会希望新任领导者能克服这些问题，投资者也希望如此[6] Teladoc Health股票交易情况 - Gorevice辞职的消息使TDOC股票在周五上午略有上涨，交易量为410万股，略低于日均交易量470万股[7]

Teladoc Health公司管理变动 - Teladoc Health宣布CEO Jason Gorevic突然离职[1] - 公司董事会暂时任命CFO Mala Murthy代替Gorevic，并聘请一家执行搜索公司确定永久性继任者[2] Teladoc Health股价表现 - Teladoc的股价在今年以来下跌了约34%，从2021年2月的最高点294.54美元跌至目前的约14美元，这是8年来的低点[3]

公司管理变动 - Jason Gorevic 离职，Mala Murthy 被任命为代理首席执行官[1] - 公司董事会已聘请执行搜索公司评估内部和外部候选人，以确定 Gorevic 的永久继任者[2] - Mala Murthy 是一位经验丰富的领导者，专注于确保股东价值，具有平衡的收入和利润增长记录[4] 业务展望 - Teladoc Health 重申了2024年第一季度和全年的指导[3]